Ingersoll Rand Free cash flow decreased by 64.6% to $163.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 26.6%, from $222.70M to $163.40M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 21.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $135.70M | $130.80M | $224.00M | $32.20M | $164.70M | $252.60M | $321.30M | $147.90M | $203.60M | $368.70M | $551.80M | $99.30M | $283.10M | $374.30M | $490.90M | $222.70M | $210.40M | $325.50M | $461.50M | $163.40M |
| QoQ Change | — | -3.6% | +71.3% | -85.6% | +411.5% | +53.4% | +27.2% | -54.0% | +37.7% | +81.1% | +49.7% | -82.0% | +185.1% | +32.2% | +31.2% | -54.6% | -5.5% | +54.7% | +41.8% | -64.6% |
| YoY Change | — | — | — | — | +21.4% | +93.1% | +43.4% | +359.3% | +23.6% | +46.0% | +71.7% | -32.9% | +39.0% | +1.5% | -11.0% | +124.3% | -25.7% | -13.0% | -6.0% | -26.6% |